Unlike many peptides with low oral bioavailability, BPC-157 stands out due to its gastric origin and high oral bioavailability
Such a clean, isolated dataset for cagrilintide monotherapy is not prominent in the peer-reviewed literature, and this gap is itself an important finding
No published safety data for the combination
Samples were tested for the presence of AIs (2-androstenol (5-androst-2-en-17-ol), 2-androstenone (5-androst-2-en-17-one), 3-androstenol (5-androst-3-en-17-ol), 3-androstenone (5-androst-3-en-17-one), 4-androstene-3,6,17 trione (6-oxo), aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), androsta-3,5-diene-7,17-dione (arimistane), exemestane, formestane, letrozole, and testolactone), and anti-estrogenic substance (bazedoxifene, clomiphene, cyclofenil, fulvestrant, ospemifene, raloxifene, tamoxifen, and toremifene) prohibited by WADA
Related compounds Stay informed Track BPC-157 with Peptide Report
Responsible planning and patience are the only real solutions
